Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "TD"

1248 News Found

TDB approves funding for MIM in MedTech
News | March 30, 2022

TDB approves funding for MIM in MedTech

Technology Development Board supports commercialisation of Metal Injection Molding of implants


WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services
Biotech | October 22, 2021

WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services

It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China


Nureca Ltd PAT at Rs 36.19 crore in Q1FY22
Healthcare | August 03, 2021

Nureca Ltd PAT at Rs 36.19 crore in Q1FY22

Nureca Ltd has reported financial results for the period ended June 30, 2021.


Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr
News | July 28, 2021

Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr

The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.


Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
News | August 01, 2025

Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr

Our specialty chemical businesses have continued to perform strongly, growing double digit YoY


Imfinzi granted Priority Review and Breakthrough Therapy Designation in US
News | July 31, 2025

Imfinzi granted Priority Review and Breakthrough Therapy Designation in US

For patients with resectable early-stage gastric and gastroesophageal junction cancers


Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr
News | July 30, 2025

Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr

The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal


Astec LifeSciences Q1 FY26 revenue up 30.3%
News | July 29, 2025

Astec LifeSciences Q1 FY26 revenue up 30.3%

The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year


Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business
People | July 29, 2025

Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business

His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors